

the global uti problem






1 out of 10 Women, 400M people



60% of UTI cases are misdiagnosed



20-30% recurrent visits



the global amr problem





WHO predicts **39M global AMR deaths** by 2050



EU aims to **reduce antibiotic use by 20%** by 2030, UK by 25%



introducing Utilizer®-ID



1
8xFaster diagnoses of UTIs

Brings gold-standard bacterial culture to the POC

Identifies key UTI pathogens covering >95% of cases

4

No investment in new lab equipment required

5

Easy to use with digital readout on smartphone

6

Patent granted in US and pending in EU.

Registered trademark. United States Patent





Utilizer®-ID step-by-step process



step 1



Dip the utilizer dipstick in patient's urine sample

step 2



Incubate dipsticks at 36°C±2°C

step 3



Photograph
dipstick by
smartphone and
process

step 4



Automated analysis and real time connectivity

clinical validation & scientific backing





Pilot **trials** at Karolinska University Hospital in Sweden



Accuracy comparable to gold-standard laboratory culture (n=300)



Accuracy better than POC sticks



Clinical validations for In Vitro Diagnostic Regulation (CE-IVDR) **certification in process** (n=500)



user feedback



> 90% easy to use


100% works in present workflow

100% recommend Utilizer®-ID



revenue forecast





- 4B€ Market
- Unit cost €3.30/Price €15
- Gross margin 78%
- Distributor share 30%
- Cash flow neutral 2029



team



Patrick Griss Tech&Business Advisor Prior Roche



Sofia Bertling Founder/CEO



Gabriella von Flittner Director, Sales & Marketing



Emre Iseri Founder/CTO



Alex van Belkum R&D Advisor Prior bioMeriuex



Joakim Arwidson



Gino Jakobsson Chief Medical Officer



Tomas Barkman VP Engineering



Hilmar Verbeek R&D Scientist



Fredrik Larsson
Consultant/
Programmer
Financial



Chunlang Wang Consultant/Algo & Al expert



Wouter van der Wijngaart Founder



Karin Andersson Chairwoman of Board



Christian Krog Jensen AlmiInvest prior KI Innovation



Juho Himberg Board Member prior CEO Aidian and S&M Thermo Fisher



Jan Bertling Board Member prior CEO Hermes Medical



Raising 5MSEK adding to granted 10 MSEK soft funding Valuation 40MSEK

Use of funds

IVDR-CE preparation, scalable production, additional health economic studies (UK, NL, DK)

NOTABLE ACHIEVEMENTS

Patented product

Clinical studies and market pilot

Backing from KOLs and distributors

Mission-driven team





acknowledgements

























Propel Sting Capital